A case report to assess the safety and efficacy of Burosumab, an investigational antibody to FGF23, in a single pediatric patient with Epidermal Nevus Syndrome and associated hypophosphatemic rickets

A case report to assess the safety and efficacy of Burosumab, an investigational antibody to FGF23, in a single pediatric patient with Epidermal Nevus Syndrome and associated hypophosphatemic rickets

Epidermal Nevus Syndrome (ENS), also known as Cutaneous Skeletal Hypophosphatemia Syndrome or Linear Sebaceous Nevus Syndrome, is caused by a mosaic somatic mutation of RAS (Rat Sarcoma genes) which leads to abnormally elevated levels of fibroblast growth factor 23 (FGF23). FGF23 is a major regulato...

Full description

Bibliographic Details
Main Authors: Carson Huynh, Andrea Gillis, Jessica Fazendin, Hussein Abdullatif
Format: Article
Language:English
Published: Elsevier 2022-12-01
Series:Bone Reports
Subjects:
Burosumab
FGF23
Hypophosphatemia
Hyperparathyroidism
Epidermal Nevus Syndrome
Online Access:http://www.sciencedirect.com/science/article/pii/S2352187222004399

Internet

http://www.sciencedirect.com/science/article/pii/S2352187222004399

Similar Items